Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI